HOME >> BIOLOGY >> NEWS
JCI table of contents: June 14, 2007

at diet-induced insulin resistance.

Uncoupling proteins act to convert stored fat into thermal energy. In the current study the authors began by showing that mice fed a high-fat diet were markedly insulin resistant, a result of defects in insulin signaling in skeletal muscle and liver. In contrast, mice overexpressing UCP3 in skeletal muscle experienced increased whole body energy expenditure and were completely protected against fat-induced defects in insulin signaling and action in these tissues. They went on to delineate the events at the cellular levels that underlie this protective mechanism and suggest that some of these cellular events may serve as excellent therapeutic targets for the treatment of type 2 diabetes.

TITLE: Overexpression of uncoupling protein 3 in skeletal muscle protects against fat-induced insulin resistance

AUTHOR CONTACT:
Gerald I. Shulman
Yale University School of Medicine, New Haven, Connecticut, USA.
Phone : (203) 737-5447; Fax: (203) 737-4059; E-mail: gerald.shulman@yale.edu

View the PDF of this article at: https://www.the-jci.org/article.php?id=13579


'"/>

Contact: Brooke Grindlinger
press_releases@the-jci.org
212-342-9006
Journal of Clinical Investigation
14-Jun-2007


Page: 1 2 3 4 5 6 7

Related biology news :

1. Antioxidant overload may underlie a heritable human disease
2. JCI table of contents: Aug. 9, 2007
3. JCI table of contents: August 1, 2007
4. US Department of Defense awards $1.6 million for implantable biochip research
5. More fish oil, less vegetable oil, better for your health
6. JCI table of contents -- July 26, 2007
7. JCI table of contents: July 19, 2007
8. JCI table of contents: July 12, 2007
9. JCI table of contents: June 21, 2007
10. Food safety begins as vegetables grow
11. Turning the tables in chemistry

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2020)... ... 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company ... Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for ... Approval of this IND allows Sentien to initiate a Phase 1/2 study with ...
(Date:8/12/2020)... Mich. (PRWEB) , ... August 11, 2020 , ... ... R&D subsidiary based in Princeton, NJ, have entered into license agreements with Housey ... and development. Both Roche and J&J have annual Research and Development spending ...
(Date:8/5/2020)... ... 05, 2020 , ... Regenative Labs has received approval from the Centers for ... them the first Wharton’s jelly allografts to be assigned a Q code and be ... the first Wharton’s jelly allograft product to be recognized as a 361 HCT/P by ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... 2020 , ... Bode Technology, a leading provider ... through its COVID-19 testing service, Bode-CARES . Bode-CARES combines high-volume clinical testing ... provides a turnkey solution that includes a comprehensive collection and virus-management program for ...
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, ... the hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. ... of Sentien’s lead product, SBI-101. Dr. Nissenson serves as an Emeritus Professor ...
(Date:7/1/2020)... (PRWEB) , ... June 29, 2020 , ... ... year to date growth of 40% in 2020, despite many obstacles created as ... MedShift aims to increase revenue for its partnered medical practices and medical manufacturers ...
(Date:6/28/2020)... ... 2020 , ... The Indoor Lab, a leading provider of sensor solutions for ... types to ensure cleanliness, distancing and occupancy with its patent pending WipeAway™ technology using ... will provide a health performance index system that scores all aspects of compliance similar ...
Breaking Biology Technology:
Cached News: